TAK NYSE
Takeda Pharmaceutical Company Limited
1W: +1.1%
1M: +9.2%
3M: +14.3%
YTD: +29.9%
1Y: +44.8%
3Y: +51.9%
5Y: +70.8%
$20.27
-0.16 (-0.78%)
Weekly Expected Move ±3.0%
$19
$20
$20
$21
$21
Credit Risk of going bust: lower than 78% of companies Debt: 32.7% of company value Bonds: $208.5M held by 194 funds, 85 bp over Treasuries → details ▾
If the stock fell to about $0.49 (down 98%), Takeda Pharmaceutical Company Limited would be worth roughly what it owes.
Total debt $31.29B against a stock market value of $64.51B.
Distance to default 9.14 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $17.29B (short-term plus half of long-term), stock volatility 21.6%; Altman Z'' 1.53. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
Total debt $31.29B against a stock market value of $64.51B.
Distance to default 9.14 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $17.29B (short-term plus half of long-term), stock volatility 21.6%; Altman Z'' 1.53. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
📊 Key Metrics
TTM$4,661B
Revenue
+4.0% YoY
$182B
Net Income
+33.1% YoY
$691B
Free Cash Flow
-21.9% YoY
66.7%
Gross Margin
16.5%
Op. Margin
9.3%
Net Margin
💰 Income Flow
How revenue becomes profit💵 Cash Flow
Where cash goes🏦 Balance Sheet
Assets = Liabilities + Equity📈 Financial Health
Profitability
ROE2.5%
ROA1.2%
ROIC2.9%
Valuation
P/E56.1
P/B1.3
EV/EBITDA0.0
Leverage
Debt/Equity0.65
Current Ratio1.14
Interest Cov.1.9x
Quality Scores
Piotroski F6/9
Altman Z—
Beneish M-2.33